CONMED
CNMD
144 hedge funds and large institutions have $1.47B invested in CONMED in 2017 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 61 increasing their positions, 40 reducing their positions, and 19 closing their positions.
534% more call options, than puts
Call options by funds: $3.82M | Put options by funds: $603K
53% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 40
4% more capital invested
Capital invested by funds: $1.42B → $1.47B (+$57.4M)
0.84% more ownership
Funds ownership: 99.74% → 100.58% (+0.84%)
4% less funds holding
Funds holding: 150 → 144 (-6)
26% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 19
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$7.82M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
+$5.58M |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$4.47M |
| 4 |
BlackRock
New York
|
+$3.99M |
| 5 |
Norges Bank
Oslo,
Norway
|
+$3.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
-$6.56M |
| 2 |
CIP
Champlain Investment Partners
Burlington,
Vermont
|
-$4.38M |
| 3 |
FHAM
Folger Hill Asset Management
New York
|
-$3.74M |
| 4 |
Russell Investments Group
London,
United Kingdom
|
-$2.57M |
| 5 |
CRM
Cramer Rosenthal McGlynn
Stamford,
Connecticut
|
-$2.14M |
CNMD Hedge Fund Activity: Q3 2017 in Review
144 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in CONMED (CNMD) for Q3 2017, worth a combined $1.47B — up 4.1% from $1.42B a quarter earlier.
Sellers outnumbered buyers: 19 funds closed out of CNMD and 14 opened new positions — a net loss of 5 holders — while 40 trimmed existing stakes and 61 added.
The largest buyer was Invesco, adding an estimated $7.82M. The largest seller was Balyasny Asset Management, exiting entirely with an estimated $6.56M sold.
- 144 institutional investors held CONMED (CNMD) as of Q3 2017, down from 150 in Q2 2017.
- Funds reported $1.47B of CONMED stock for Q3 2017, up 4.1% quarter-over-quarter.
- 14 funds opened new CONMED positions in Q3 2017 and 19 closed out, a net change of -5 holders.
- The largest CONMED buyer in Q3 2017 was Invesco, an estimated $7.82M added.
- The largest CONMED seller in Q3 2017 was Balyasny Asset Management, an estimated $6.56M sold.
Based on aggregated 13F filings for Q3 2017.